Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
Open accessAbstract
Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) remains a threat to cause epidemics as evidenced by recent sporadic cases in China. In this communication, we evaluated the efficacy and safety of two SARS vaccine candidates based on the recombinant modified vaccinia Ankara (MVA) expressing SARS-CoV spike or nucleocapsid proteins in ferrets. No clinical signs were observed in all the ferrets challenged with SARS-CoV. On the other hand, vaccination did not prevent SARS-CoV infection in ferrets. In contrast, immunized ferrets (particularly those immunized with rMVA-spike) exhibited significantly stronger inflammatory responses and focal necrosis in liver tissue after SARS-CoV challenge than control animals. Thus, our data suggest that enhanced hepatitis is linked to vaccination with rMVA expressing SARS-CoV antigens.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In animal models of other coronaviruses and prior inactivated RSV or measles vaccines, VAERD is usually linked to Th2-biased CD4+ responses with elevated IL-4, IL-5, or IL-13.
“In animal models of infections with other coronaviruses and for previous whole-cell inactivated vaccines developed for respiratory syncytial virus and measles virus, VAERD has usually been associated with the development of T helper 2 cell (TH2 cell)-biased CD4+ T cell responses, with significantly increased levels of interleukin-4 (IL-4), IL-5 and/or IL-13 (refs12,126,165–174).”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [171]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R. P., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,477 · see citing works
The Genome Sequence of the SARS-Associated Coronavirus
Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A. R., Butterfield, Y. S. N., Khattra, J. S., Asano, J. K., Barber, S., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,017 · see citing works
Self-citationSARS virus infection of cats and ferrets
Martina, B. E. E., Haagmans, B. L., Kuiken, T., Fouchier, R. A. M., Rimmelzwaan, G. F., van Amerongen, G., Peiris, M. J. S., Lim, W. W. L., & Osterhaus, A. D. M. E. (2003) · Nature · doi:10.1038/425915a · Cited by 571 · see citing works
SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases
Chau, T., Lee, K.-C., Yao, H., Tsang, T. Y. O., Chow, T., Yeung, Y.-C., Choi, K., Tso, Y.-K., Lau, T., Lai, S.-T., et al. (2004) · Hepatology · doi:10.1002/hep.20111 · Cited by 422 · see citing works
Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression
Chakrabarti, S., Sisler, J. R., & Moss, B. A. (1997) · BioTechniques · doi:10.2144/97236st07 · Cited by 391 · see citing works
Antibody‐dependent enhancement of viral infection: molecular mechanisms and in vivo implications
Takada, A., & Kawaoka, Y. (2003) · Reviews in Medical Virology · doi:10.1002/rmv.405 · Cited by 332 · see citing works
Collins, A. R., Knobler, R. L., Powell, H., & Buchmeier, M. J. (1982) · Virology · doi:10.1016/0042-6822(82)90095-2 · Cited by 317 · see citing works
Falkner, F. G., & Moss, B. A. (1988) · Journal of Virology · doi:10.1128/jvi.62.6.1849-1854.1988 · Cited by 317 · see citing works
Antibody-Dependent Enhancement of Virus Infection and Disease
Cancel-Tirado, S. M., & Yoon, K. J. (2003) · Viral Immunology · doi:10.1089/088282403763635465 · Cited by 316 · see citing works
Vennema, H., de Groot, R. J., Harbour, D. A., Dalderup, M. J. M., Gruffydd-Jones, T., Horzinek, M. C., & Spaan, W. J. M. (1990) · Journal of Virology · doi:10.1128/jvi.64.3.1407-1409.1990 · Cited by 276 · see citing works
Weiss, R. C., & Scott, F. W. (1981) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/0147-9571(81)90003-5 · Cited by 242 · see citing works
Fleming, J. O., Stohlman, S. A., Harmon, R. C., Lai, M. M. C., Frelinger, J. A., & Weiner, L. P. (1983) · Virology · doi:10.1016/0042-6822(83)90498-1 · Cited by 163 · see citing works
Olsen, C. W. (1993) · Veterinary Microbiology · doi:10.1016/0378-1135(93)90126-r · Cited by 119 · see citing works
Susceptibility of Pigs and Chickens to SARS Coronavirus
Weingartl, H. M., Copps, J. S., DREBOT, M. A., Marszal, P., Smith, G. A., Gren, J., Andonova, M., Pasick, J. M. M., Kitching, P., & Czub, M. (2004) · Emerging infectious diseases · doi:10.3201/eid1002.030677 · Cited by 85 · see citing works
Self-citationComparison of assays for the detection of West Nile virus antibodies in chicken serum.
Weingartl, H. M., DREBOT, M. A., Hubálek, Z., Halouzka, J., Andonova, M., Dibernardo, A., Cottam-Birt, C., Larence, J. E., & Marszal, P. (2003) · Europe PMC (PubMed Central) · Cited by 58 · see citing works
Self-citationAdverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus
Glansbeek, H. L., Haagmans, B. L., Lintelo, E. G. T., Egberink, H. F., Duquesne, V., Aubert, A., Horzinek, M. C., & Rottier, P. J. M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-1-1 · Cited by 50 · see citing works
Virology: SARS virus infection of cats and ferrets
Bartlett, J. G. (2004) · Infectious Diseases in Clinical Practice · Cited by 34 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098 · see citing works
Coronaviruses — drug discovery and therapeutic options
Zumla, A. I., Chan, J. F., Azhar, E. I., Hui, D. S. C., & Yuen, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,689 · see citing works
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,649 · see citing works
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615 · see citing works
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Song, Z., Xu, Y., Bao, L., Zhang, L., Yü, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., & Qin, C. (2019) · Viruses · doi:10.3390/v11010059 · Cited by 1,268 · see citing works
Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus
Weiss, S. R., & Navas-Martin, S. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.4.635-664.2005 · Cited by 1,256 · see citing works
Distinct conformational states of SARS-CoV-2 spike protein
Cai, Y., Zhang, J., Xiao, T., Peng, H., Sterling, S. M., Walsh, R. M., Rawson, S., Rits-Volloch, S., & Chen, B. (2020) · Science · doi:10.1126/science.abd4251 · Cited by 1,221 · see citing works
Coronavirus Infections in Children Including COVID-19
Zimmermann, P., & Curtis, N. C. (2020) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002660 · Cited by 1,104 · see citing works
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015 · see citing works
Genotype and phenotype of COVID-19: Their roles in pathogenesis
Mousavizadeh, L., & Ghasemi, S. (2020) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.03.022 · Cited by 961 · see citing works
Weiss, S. R., & Leibowitz, J. L. (2011) · Advances in virus research · doi:10.1016/b978-0-12-385885-6.00009-2 · Cited by 899 · see citing works
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676 · see citing works
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560 · see citing works
Zimmermann, P., & Curtis, N. C. (2020) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-320338 · Cited by 502 · see citing works
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485 · see citing works
Coronavirus vaccine development: from SARS and MERS to COVID-19
Li, Y.-D., Chi, W.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00695-2 · Cited by 461 · see citing works
Geller, C., Varbanov, M., & Duval, R. E. (2012) · Viruses · doi:10.3390/v4113044 · Cited by 433 · see citing works
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375 · see citing works
The COVID-19 pandemic face mask waste: A blooming threat to the marine environment
Dharmaraj, S., Ashokkumar, V., Hariharan, S., Manibharathi, A., Show, P. L., Chong, C. T., & Ngamcharussrivichai, C. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.129601 · Cited by 311 · see citing works
Prospects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261 · see citing works
Yasui, F., Kai, C., Kitabatake, M., Inoue, S., Yoneda, M., Yokochi, S., Kase, R., Sekiguchi, S., Morita, K., Hishima, T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6337 · Cited by 248 · see citing works
Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus
Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L., & Tan, W. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01781 · Cited by 224 · see citing works
Contriving Multi-Epitope Subunit of Vaccine for COVID-19: Immunoinformatics Approaches
Dong, R., Chu, Z., Yu, F., & Zha, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01784 · Cited by 224 · see citing works
The Evolution of Poxvirus Vaccines
Sánchez-Sampedro, L., Perdiguero, B., Mejías‐Pérez, E., García‐Arriaza, J., Pilato, M. D., & Estéban, M. (2015) · Viruses · doi:10.3390/v7041726 · Cited by 217 · see citing works
Accelerating antiviral drug discovery: lessons from COVID-19
von Delft, A., Hall, M. D., Kwong, A. D., Purcell, L. A., Saikatendu, K. S., Schmitz, U., Tallarico, J. A., & Lee, A. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00692-8 · Cited by 223 · see citing works
Ryan, K. A., Bewley, K. R., Fotheringham, S. A., Slack, G. S., Brown, P. J., Hall, Y., Wand, N. I. V., Marriott, A. C., Cavell, B. E., Tree, J. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20439-y · Cited by 188 · see citing works
Pimentel, T. A. P. F., Yan, Z., Jeffers, S. A., Holmes, K. V., Hodges, R. S., & Burkhard, P. (2008) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2008.00746.x · Cited by 182 · see citing works
Du, L., Zhao, G., He, Y., Guo, Y., Zheng, B., Jiang, S., & Zhou, Y. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.10.031 · Cited by 182 · see citing works
Roper, R. L., & Rehm, K. E. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.43 · Cited by 179 · see citing works
Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains
Padron-Regalado, E. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00300-x · Cited by 178 · see citing works
Learning from the past: development of safe and effective COVID-19 vaccines
Su, S., Du, L., & Jiang, S. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00462-y · Cited by 164 · see citing works
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
Ejemel, M., Li, Q., Hou, S., Schiller, Z. A., Tree, J. A., Wallace, A., Amcheslavsky, A., Yılmaz, N. K., Buttigieg, K. R., Elmore, M. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18058-8 · Cited by 182 · see citing works
Current advances in the development of SARS-CoV-2 vaccines
Awadasseid, A., Wu, Y., Tanaka, Y., & Zhang, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.52569 · Cited by 164 · see citing works
Current advancements and potential strategies in the development of MERS-CoV vaccines
Zhang, N., Jiang, S., & Du, L. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.912134 · Cited by 160 · see citing works
Emerging Respiratory Viruses: Challenges and Vaccine Strategies
Gillim-Ross, L., & Subbarao, K. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.00005-06 · Cited by 157 · see citing works
Kapadia, S. U., Rose, J. K., Lamirande, E. W., Vogel, L., Subbarao, K., & Roberts, A. (2005) · Virology · doi:10.1016/j.virol.2005.06.016 · Cited by 155 · see citing works
A comparative overview of COVID-19, MERS and SARS: Review article
Liu, J., Xie, W., Wang, Y., Xiong, Y., Chen, S., Han, J., & Wu, Q. (2020) · International Journal of Surgery · doi:10.1016/j.ijsu.2020.07.032 · Cited by 143 · see citing works
Du, L., Zhao, G., Lin, Y., Sui, H., Chan, C. C. S., Ma, S., He, Y., Jiang, S., Wu, C. Y., Yuen, K., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.948 · Cited by 136 · see citing works
Gómez, C. E., Nájera, J. L., Krupa, M., & Estéban, M. (2008) · Current Gene Therapy · doi:10.2174/156652308784049363 · Cited by 139 · see citing works
DiNapoli, J. M., Kotelkin, A., Yang, L., Elankumaran, S., Murphy, B. R., Samal, S. K., Collins, P. L., & Bukreyev, A. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703584104 · Cited by 136 · see citing works
He, Y., Li, J., Heck, S., Lustigman, S., & Jiang, S. (2006) · Journal of Virology · doi:10.1128/jvi.00083-06 · Cited by 135 · see citing works
Kim, E., Okada, K., Kenniston, T., Raj, V. S., AlHajri, M. M., Farag, E., Alhajri, F. H., Osterhaus, A. D. M. E., Haagmans, B. L., & Gambotto, A. A. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.08.058 · Cited by 135 · see citing works
Ma, C., Wang, L., Tao, X., Zhang, N., Yang, Y., Tseng, C.-T. K., Li, F., Zhou, Y., Jiang, S., & Du, L. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.08.086 · Cited by 131 · see citing works
Du, L., Zhao, G., Chan, C. C. S., Sun, S., Chen, M., Liu, Z., Guo, H., He, Y., Zhou, Y., Zheng, B., et al. (2009) · Virology · doi:10.1016/j.virol.2009.07.018 · Cited by 129 · see citing works
Prospects for a MERS-CoV spike vaccine
Zhou, Y., Jiang, S., & Du, L. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1506702 · Cited by 126 · see citing works
COVID-19: Mechanisms of Vaccination and Immunity
Speiser, D. E., & Bachmann, M. F. (2020) · Vaccines · doi:10.3390/vaccines8030404 · Cited by 123 · see citing works
SARS-CoV-2 vaccines: Lights and shadows
Angeli, F., Spanevello, A., Reboldi, G., Visca, D., & Verdecchia, P. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.04.019 · Cited by 122 · see citing works
Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease
Enjuanes, L., DeDiego, M. L., Álvarez, E. A., Deming, D., Sheahan, T., & Baric, R. S. (2007) · Virus Research · doi:10.1016/j.virusres.2007.01.021 · Cited by 119 · see citing works
Spruth, M., Kistner, O., Savidis-Dacho, H., Hitter, E., Crowe, B. A., Gerenčer, M., Brühl, P., Grillberger, L., Reiter, M., Tauer, C., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.055 · Cited by 121 · see citing works
Malczyk, A. H., Kupke, A., Prüfer, S., Scheuplein, V., Hutzler, S., Kreuz, D., Beißert, T., Bauer, S., Hubich-Rau, S., Tondera, C., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01815-15 · Cited by 116 · see citing works
Neutralizing antibodies for the treatment of COVID-19
Jiang, S.-B., Zhang, X., Yang, Y., Hotez, P., & Du, L. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00660-2 · Cited by 91 · see citing works
Goepfert, P., Fu, B., Chabanon, A.-L., Bonaparte, M. I., Davis, M., Essink, B. J., Frank, I., Haney, O., Janosczyk, H., Keefer, M. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00147-x · Cited by 112 · see citing works
Pathology of Experimental SARS Coronavirus Infection in Cats and Ferrets
van den Brand, J. M. A., Haagmans, B. L., Leijten, L. M. E., van Riel, D. A. J., Martina, B. E. E., Osterhaus, A. D. M. E., & Kuiken, T. (2008) · Veterinary Pathology · doi:10.1354/vp.45-4-551 · Cited by 113 · see citing works
Hotez, P. J., Bottazzi, M. E., & Corry, D. B. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.04.005 · Cited by 114 · see citing works
Progress and Concept for COVID‐19 Vaccine Development
Wu, S. (2020) · Biotechnology Journal · doi:10.1002/biot.202000147 · Cited by 114 · see citing works
SARS-CoV-2 Vaccine Development: Current Status
Poland, G. A., Ovsyannikova, I. G., Crooke, S. N., & Kennedy, R. B. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.07.021 · Cited by 112 · see citing works
Kaur, N., Singh, R., Dar, Z., Bijarnia, R. K., Dhingra, N., & Kaur, T. (2020) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2020.104490 · Cited by 110 · see citing works
Medicinal Plants, Phytochemicals, and Herbs to Combat Viral Pathogens Including SARS-CoV-2
Anand, A. V., Balasubramanian, B., Kaviya, M., Kathirvel, B., Parithathvi, A., Meyyazhagan, A., Senthilkumar, N., Velayuthaprabhu, S., Muthukrishnan, S., Al-Dhabi, N. A., et al. (2021) · Molecules · doi:10.3390/molecules26061775 · Cited by 110 · see citing works
MVA and NYVAC as Vaccines against Emergent Infectious Diseases and Cancer
Gómez, C. E., Nájera, J. L., Krupa, M., Perdiguero, B., & Estéban, M. (2011) · Current Gene Therapy · doi:10.2174/156652311795684731 · Cited by 108 · see citing works
The SARS-CoV ferret model in an infection–challenge study
Chu, Y., Ali, G. D., Jia, F., Li, Q., Kelvin, D. J., Couch, R. C., Harrod, K. S., Hutt, J. A., Cameron, C., Weiss, S. R., et al. (2008) · Virology · doi:10.1016/j.virol.2007.12.032 · Cited by 107 · see citing works
Roberts, A., Thomas, W. D., Guarner, J., Lamirande, E. W., Babcock, G. J., Greenough, T. C., Vogel, L., Hayes, N., Sullivan, J. L., Zaki, S. R., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/500143 · Cited by 103 · see citing works
Molecular Biology of the SARS-Coronavirus
Lal, S. K. (2010) · Springer eBooks · doi:10.1007/978-3-642-03683-5 · Cited by 102 · see citing works
Chen, W., Tao, X., Agrawal, A. S., Algaissi, A. A., Peng, B., Pollet, J. B. K., Strych, U., Bottazzi, M. E., Hotez, P. J., Lustigman, S., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.09.061 · Cited by 102 · see citing works
Vaccines for the prevention against the threat of MERS-CoV
Du, L., Tai, W., Zhou, Y., & Jiang, S. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1167603 · Cited by 101 · see citing works
Tse, L. V., Meganck, R. M., Graham, R. L., & Baric, R. S. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00658 · Cited by 99 · see citing works
Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines
Flanagan, K. L., Best, E., Crawford, N. W., Giles, M., Koirala, A., Macartney, K. K., Russell, F. M., Teh, B. W., & Wen, S. C.-H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.579250 · Cited by 95 · see citing works
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Chakraborty, S., Mallajosyula, V. V. A., Tato, C. M., Tan, G. S., & Wang, T. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.014 · Cited by 87 · see citing works
See, R. H., Petric, M., Lawrence, D. J., Mok, C. P. Y., Rowe, T., Zitzow, L. A., Karunakaran, K. P., Voss, T. G., Brunham, R. C., Gauldie, J., et al. (2008) · Journal of General Virology · doi:10.1099/vir.0.2008/001891-0 · Cited by 85 · see citing works
Khan, T., Islam, M. J., Parihar, A., Islam, R., Jerin, T. J., Dhote, R., Ali, M., Laura, F. K., & Halim, M. A. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100578 · Cited by 84 · see citing works
Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions
Gavor, E., Choong, Y. K., Er, S. Y., Sivaraman, H., & Sivaraman, J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.09.004 · Cited by 81 · see citing works
Targets and strategies for vaccine development against SARS-CoV-2
Malik, J. A., Mulla, A. H., Farooqi, T., Pottoo, F. H., Anwar, S., & Rengasamy, K. R. R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111254 · Cited by 81 · see citing works
Hashem, A. M., Algaissi, A. A., Agrawal, A. S., Alamri, S. S., Alhabbab, R. Y., Sohrab, S. S., Almasoud, A. S., Alharbi, N. K., Peng, B., Russell, M. S., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz137 · Cited by 72 · see citing works
Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses
Gartlan, C., Tipton, T., Salguero, F. J., Sattentau, Q. J., GORRINGE, A. R., & Carroll, M. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.882972 · Cited by 77 · see citing works
Lokugamage, K. G., Iwata‐Yoshikawa, N., Ito, N., Watts, D. M., Wyde, P. R., Wang, N., Newman, P. C., Tseng, C.-T. K., Peters, C. J., & Makino, S. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.11.092 · Cited by 73 · see citing works
Membrane Protein of Human Coronavirus NL63 Is Responsible for Interaction with the Adhesion Receptor
Naskalska, A., Dąbrowska, A., Szczepański, A., Milewska, A., Jasik, K. P., & Pyrć, K. (2019) · Journal of Virology · doi:10.1128/jvi.00355-19 · Cited by 73 · see citing works
Arashkia, A., Jalilvand, S., Mohajel, N., Afchangi, A., Azadmanesh, K., Salehi-Vaziri, ., Fazlalipour, M., Pouriayevali, M. H., Jalali, T., Nasab, S. D. M., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2183 · Cited by 72 · see citing works
Roberts, A., Lamirande, E. W., Vogel, L., Baras, B., Goossens, G., Knott, I., Chen, J., Ward, J. M., Vassilev, V. B., & Subbarao, K. (2010) · Viral Immunology · doi:10.1089/vim.2010.0028 · Cited by 70 · see citing works
Cameron, M. J., Kelvin, A. A., Leon, A. J., Cameron, C., Ran, L., Xu, L., Chu, Y.-K., Danesh, A., Yuan, F., Li, Q., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045842 · Cited by 68 · see citing works
Lu, M., Dravid, P., Zhang, Y., Trivedi, S., Li, A., Harder, O. E., Mahesh, K. C., Chaiwatpongsakorn, S., Zani, A., Kenney, A. D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026153118 · Cited by 65 · see citing works
Vaccines against Coronaviruses: The State of the Art
Conte, C., Sogni, F., Affanni, P., Veronesi, L., Argentiero, A., & Esposito, S. (2020) · Vaccines · doi:10.3390/vaccines8020309 · Cited by 60 · see citing works
Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design
Wang, D., Mai, J., Zhou, W., Yu, W., Zhan, Y., Wang, N., Epstein, N. D., & Yang, Y. (2020) · Vaccines · doi:10.3390/vaccines8030355 · Cited by 58 · see citing works
Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection
Yilmaz, I. C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Guvencli, N., Aydin, Y., Gungor, B., et al. (2021) · Allergy · doi:10.1111/all.15091 · Cited by 59 · see citing works
Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Tong, T. R. S.-W. (2009) · Infectious Disorders - Drug Targets · doi:10.2174/187152609787847659 · Cited by 55 · see citing works
Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
Al‐Kassmy, J., Pedersen, J., & Kobinger, G. (2020) · Viruses · doi:10.3390/v12080861 · Cited by 56 · see citing works
Severe Acute Respiratory Syndrome Coronavirus Infection in Vaccinated Ferrets
Darnell, M. E. R., Plant, E. P., Watanabe, H., Byrum, R., Claire, M. S., Ward, J. M., & Taylor, D. R. (2007) · The Journal of Infectious Diseases · doi:10.1086/522431 · Cited by 54 · see citing works
Uskoković, V. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0163 · Cited by 51 · see citing works
Du, L., Zhao, G., Chan, C. C. S., Li, L., He, Y., Zhou, Y., Zheng, B., & Jiang, S. (2010) · Viral Immunology · doi:10.1089/vim.2009.0090 · Cited by 47 · see citing works
Llanes, A., Restrepo, C. M., Zuleima Caballero, E., Rajeev, S., Kennedy, M. A., & Lleonart, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124546 · Cited by 47 · see citing works
Ferrets are valuable models for SARS-CoV-2 research
Ciurkiewicz, M., Armando, F., Schreiner, T., de Buhr, N., Pilchová, V., Krupp-Buzimikic, V., Gabriel, G., von Köckritz‐Blickwede, M., Baumgärtner, W., Schulz, C., et al. (2022) · Veterinary Pathology · doi:10.1177/03009858211071012 · Cited by 43 · see citing works
Kane, Y., Wong, G., & Gao, G. F. (2023) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-020420-025011 · Cited by 42 · see citing works
State-of-the-Art of Nanodiagnostics and Nanotherapeutics against SARS-CoV-2
Derakhshan, M. A., Amani, A., & Majidi, R. F. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c22381 · Cited by 42 · see citing works
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Tong, T. R. S.-W. (2006) · Perspectives in medical virology · doi:10.1016/s0168-7069(06)16004-8 · Cited by 41 · see citing works
Improving immunological insights into the ferret model of human viral infectious disease
Wong, J., Layton, D., Wheatley, A. K., & Kent, S. J. (2019) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12687 · Cited by 38 · see citing works
Kreijtz, J. H. C. M., Suezer, Y., Bodewes, R., Schwantes, A., van Amerongen, G., Verburgh, R. J., de Mutsert, G., van den Brand, J. M. A., Trierum, S. E. V.-V., Kuiken, T., et al. (2010) · Journal of General Virology · doi:10.1099/vir.0.024885-0 · Cited by 40 · see citing works
Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
Perdiguero, B., Pérez, P., Marcos-Villar, L., Albericio, G., Astorgano, D., Álvarez, E., Sin, L., Gómez, C. E., García‐Arriaza, J., & Estéban, M. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168173 · Cited by 39 · see citing works
The impact of immuno-aging on SARS-CoV-2 vaccine development
Connors, J. R., Bell, M. R., Marcy, J., Kutzler, M. A., & Haddad, E. K. (2021) · GeroScience · doi:10.1007/s11357-021-00323-3 · Cited by 38 · see citing works
Immune Response to SARS-CoV-2 Vaccines
Bellamkonda, N., Lambe, U. P., Sawant, S. A., Nandi, S. S., Chakraborty, C., & Shukla, D. (2022) · Biomedicines · doi:10.3390/biomedicines10071464 · Cited by 35 · see citing works
Razali, R., Asis, H., & Budiman, C. (2021) · Microorganisms · doi:10.3390/microorganisms9122481 · Cited by 36 · see citing works
Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus
Tripet, B., Kao, D. J., Jeffers, S. A., Holmes, K. V., & Hodges, R. S. (2006) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.03.019 · Cited by 36 · see citing works
Khalaj‐Hedayati, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/7201752 · Cited by 35 · see citing works
- Authors
- CZUB, M., WEINGARTL, H., CZUB, S., HE, R., & CAO, J.
- Affiliations
- Canadian Science Centre for Human and Animal Health (CA)
- University of Manitoba (CA)
- Corresponding author
- CAO, J
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2005-03-18
- Volume
- 23
- Issue
- 17-18
- Pages
- 2273-2279
- ISSN
- 0264-410X (ISSN-L)
- PMC
- PMC7115540
- OpenAlex
- W2169462787
- Cited by
- 180
- References
- 17
- Citations by year
- 2026: 1 · 2024: 4 · 2023: 9 · 2022: 14 · 2021: 36 · 2020: 55 · 2019: 5 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 4 · 2013: 1 · 2012: 4
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Vaccine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Food Inspection Agency
- Health Canada
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Immunology and Microbiology › Virology › Poxvirus research and outbreaks
- Keywords
- SARS-CoV, modified vaccinia Ankara, recombinant vaccine, spike protein, nucleocapsid protein, ferrets, vaccine efficacy, vaccine safety, liver necrosis, inflammation
- MeSH terms
- Coronavirus Nucleocapsid Proteins, Animals, Antigens, Viral, Base Sequence, DNA, Viral, Ferrets, Hepatitis, Viral, Animal, Male, Membrane Glycoproteins, RNA, Viral, Vaccines, Synthetic, Viral Envelope Proteins, Viral Vaccines, Nucleocapsid Proteins, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
